The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

Some people live with IgA nephropathy for 10 or more years without symptoms. But eventually, damage from IgA nephropathy can badly scar your kidneys and lead to other issues. What Are the Symptoms ...

Only about 200,000 people in the U.S. have IgA nephropathy. You can get it at any age, but symptoms usually happen before age 40. Autoimmune diseases cause your body’s natural defense system ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

IgA nephropathy causes inflammation and damage in these blood vessels. As a result, blood leaks into the urine. This can ...

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Andrew S. Bomback, MD, MPH, recalls a patient from over a decade ago, who traveled to New York for a second opinion on his IgA nephropathy diagnosis. The patient had researched his condition and ...

Early detection and treatment of IgA nephropathy are critical for better outcomes, but many patients present with advanced kidney disease, often due to a delay in diagnosis. This delay is largely ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN ... within 10 to 20 years of diagnosis. Each year, approximately 25 ...

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.